...
首页> 外文期刊>Oncology letters >Mechanisms by which CXCR4/CXCL12 cause metastatic behavior in pancreatic cancer
【24h】

Mechanisms by which CXCR4/CXCL12 cause metastatic behavior in pancreatic cancer

机译:CXCR4 / CXCL12在胰腺癌中引起转移性行为的机制

获取原文
获取原文并翻译 | 示例

摘要

C-X-C motif chemokine receptor (CXCR) 4/CXCL12 is associated with tumor invasion and metastasis in pancreatic cancer. The present study aimed to investigate the possible mechanisms behind this process by studying the association between the expression of CXCR4 and numerous molecular markers. A total of 60 patients with pancreatic cancer who had been treated with radical surgery between July 2012 and February 2016 were included in the present study. The expression of CXCR4/CXCL12 in primary pancreatic cancer lesions, tissues adjacent to cancerous tissue, non-cancerous pancreatic tissues and in the surrounding lymph nodes was evaluated by immunohistochemistry. Expression levels of four candidate biomarkers [vascular endothelial growth factor-C (VEGF-C), Ki-67, matrix metal-loproteinase 2 (MMP-2) and beta-catenin] were also evaluated. The correlation between CXCR4 and these four biomarkers was assessed. CXCR4 (CXCL12) expression levels were higher in pancreatic cancer 56.7% (86.7%), paracancerous tissue 50.0% (85.0%) and surrounding lymph nodes 53.3% (80.0%), compared with in normal tissues 18.3% (45.0%). CXCR4 expression was significantly associated with the lymph node metastasis of tumors (P=0.001), pathological type (P=0.037) and tumor-node-metastasis stage (P=0.031). CXCR4 expression exhibited a positive correlation with VEGF-C (r=0.417; P=0.001), Ki-67 (r=0.316; P=0.014), MMP-2 (r=0.284; P=0.028) and beta-catenin (r=0.368; P=0.04). Furthermore, logistic regression analysis revealed VEGF-C (beta=1.722; P=0.005) and Ki-67 (beta=1.196; P=0.047) to be two biomarkers that cause metastasis via CXCR4. CXCR4/CXCL12 is closely associated with tumor grade and lymphatic metastasis. VEGF-C and Ki-67 are two important biomarkers, through which CXCR4 initiates metastatic behavior in pancreatic cancer. Therefore, angiogenesis inhibitors will continue to be effective agents in treating pancreatic cancer.
机译:C-X-C主题趋化因子受体(CXCR)4 / CXCL12与胰腺癌中的肿瘤侵袭和转移相关。本研究旨在通过研究CXCR4和许多分子标记的表达之间的关联来研究该过程背后的可能机制。在本研究中纳入了2012年7月至2016年2月至2016年2月至2016年2月之间的激进手术治疗的60例胰腺癌。免疫组化评价了癌癌病变,癌组织,非癌组织和周围淋巴结邻近的组织的CXCR4 / CXCL12的表达。还评价了四种候选生物标志物的表达水平[血管内皮生长因子-C(VEGF-C),KI-67,基质金属 - 疏蛋白酶2(MMP-2)和β-连环蛋白]。评估CXCR4与这四种生物标志物之间的相关性。 CXCR4(CXCL12)表达水平在胰腺癌中较高56.7%(86.7%),副血管组织50.0%(85.0%)和周围淋巴结53.3%(80.0%),与正常组织相比18.3%(45.0%)。 CXCR4表达与肿瘤的淋巴结转移显着相关(P = 0.001),病理型(P = 0.037)和肿瘤节点转移阶段(P = 0.031)。 CXCR4表达表现出与VEGF-C(r = 0.417; p = 0.001)的正相关,Ki-67(r = 0.316; p = 0.014),mmp-2(r = 0.284; p = 0.028)和beta-catenin( r = 0.368; p = 0.04)。此外,Logistic回归分析显示VEGF-C(β= 1.722; p = 0.005)和Ki-67(β= 1.196; p = 0.047),是通过CXCR4导致转移的两种生物标志物。 CXCR4 / CXCL12与肿瘤级和淋巴结转移密切相关。 VEGF-C和KI-67是两个重要的生物标志物,CXCR4在胰腺癌中引发转移性行为。因此,血管生成抑制剂将在治疗胰腺癌中继续是有效的药剂。

著录项

  • 来源
    《Oncology letters 》 |2018年第1期| 共6页
  • 作者单位

    Shandong Univ Shandong Acad Med Sci Shandong Canc Hosp Dept Pathol Jinan 250117 Shandong;

    Shandong Univ Shandong Acad Med Sci Shandong Canc Hosp Dept Oncol Jinan 250117 Shandong;

    Shandong Univ Shandong Acad Med Sci Shandong Canc Hosp Dept Pathol Jinan 250117 Shandong;

    Shandong Univ Shandong Acad Med Sci Shandong Canc Hosp Dept Oncol Jinan 250117 Shandong;

    Shandong Univ Shandong Acad Med Sci Shandong Canc Hosp Dept Hepatol 440 Jiyan Rd Jinan 250117;

  • 收录信息
  • 原文格式 PDF
  • 正文语种 eng
  • 中图分类 肿瘤学 ;
  • 关键词

    CXCR4/CXCL12; pancreatic cancer; mechanism; biomarkers;

    机译:CXCR4 / CXCL12;胰腺癌;机制;生物标志物;

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号